network member

Weill Cornell Medicine

New York, New York

About Network Member

website: Weill Cornell Medicine

https://meyercancer.weill.cornell.edu/about

Currently Enrolling

HCRN-GU21-551

ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Cancer areas:Bladder

Icahn School of Medicine at Mount Sinai

Moffitt Cancer Center

Rutgers Cancer Institute

Weill Cornell Medicine

See clinicaltrials.gov

Currently Enrolling

HCRN-GU22-587

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

Cancer areas:Kidney

Beth Israel Deaconess Medical Center

Columbia University Irving Medical Center

Dana-Farber Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

John Theurer Cancer Center at Hackensack Meridian Health

Moores Cancer Center at UC San Diego

Penn Medicine Abramson Cancer Center

The Ohio State University

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

Weill Cornell Medicine

Winship Cancer Institute of Emory University

Yale Cancer Center

See clinicaltrials.gov

Currently Enrolling

HCRN-MCC20-443

A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (iPRRT Study)

Cancer areas:Merkel Cell Carcinoma

University of Iowa Holden Comprehensive Cancer Center

University of Wisconsin Carbone Cancer Center

Weill Cornell Medicine

See clinicaltrials.gov